Infections or Vaccines Associated with Finkelstein-Seidlmayer Vasculitis: Systematic Review

Gabriel Bronz1 · Céline Betti1 · Pietro O. Rinoldi1 · Lisa Kottanattu1,2 · Mario G. Bianchetti2,3 · Danilo Consolascio3 · Marcel M. Bergmann4,5 · Gregorio P. Milani6,7 · Benedetta Terziroli Beretta Piccoli2,8 · Sebastiano A. G. Lava9,10

Accepted: 18 April 2022 / Published online: 12 May 2022
© The Author(s) 2022

Abstract

Finkelstein-Seidlmayer vasculitis, also referred to as acute hemorrhagic edema of young children, is a rare small-vessel leukocytoclastic vasculitis. This condition is skin-limited, mainly affects infants up to 2 years of age and spontaneously remits. It has been suggested that an infection or a vaccine precede (by ≤ 14 days) this vasculitis. To better understand the interplay between infections or vaccines and Finkelstein-Seidlmayer vasculitis, we utilized the data contained in the Acute Hemorrhagic Edema Bibliographic Database AHEBID. The database, initiated in 2019, is being regularly updated, encompasses the entire original literature on Finkelstein-Seidlmayer vasculitis published after the original description and is attainable on request. The possible existence of an infectious or a vaccine precursor was addressed in 447 cases. Most cases were preceded by an infection (N = 384; 86%), by a vaccination (N = 20; 4.4%), or both an infection and a vaccination (N = 17; 3.8%). No precursor was reported in the remaining cases (N = 26; 5.8%). Two distinct infections preceded the onset of the vasculitis in 11 of the 381 cases with infection-associated Finkelstein-Seidlmayer vasculitis. The following infectious precursors were reported: upper respiratory tract infection (N = 292); acute gastroenteritis (N = 40); a benign febrile infection (N = 36); lower respiratory tract infection (N = 22); further infections (N = 8). The temporal relationship between the infectious precursor and the onset of the skin eruption was detailed in 336 cases: 54 cases developed before resolution and 282 after resolution of the infection. In conclusion, most cases of Finkelstein-Seidlmayer vasculitis are preceded by an infection. In a minority of cases, this skin vasculitis develops before resolution of the infection. In most cases, however, this vasculitis develops after resolution of the infection. More rarely, this vasculitis is preceded by a vaccination.

Keywords  Acute hemorrhagic edema of young children · Cockade purpura with edema · Finkelstein-Seidlmayer vasculitis · Infection · Precursor · Small-vessel leukocytoclastic vasculitis · Vaccination

* Benedetta Terziroli Beretta Piccoli
benedetta.terziroli@hin.ch

1 Pediatric Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
2 Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
3 Family Medicine, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
4 Centro Pediatrico del Mendrisiotto, Mendrisio, Switzerland
5 Pediatric Allergy Unit, Department of Woman, Child and Adolescent, University Hospitals of Geneva, Geneva, Switzerland
6 Pediatric Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
7 Department of Clinical Sciences and Community Health, Università Degli Studi Di Milano, Milan, Italy
8 Epatocentro Ticino, Lugano, Switzerland
9 Pediatric Cardiology Unit, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
10 Heart Failure and Transplantation, Department of Paediatric Cardiology, Great Ormond Street Hospital, London, UK

© Springer
Introduction

Finkelstein-Seidlmayer vasculitis, also referred to as acute hemorrhagic edema of young children, cockade purpura with edema, infantile erythema multiforme, or infantile Henoch-Schönlein purpura, is a rare immune-mediated small-vessel leukocytoclastic vasculitis [1–4]. This condition is skin-limited, mainly occurs in infants up to 2 years of age, spontaneously remits in a maximum of 3 weeks and does not tend to recur [1–4]. Affected patients are well-appearing and acutely present with widespread and symmetrically distributed annular or nummular eruptions and edema [1–4]. The annular or nummular eruptions are distributed over the legs, feet, face, arms, ears, trunk, and genitals in that order of frequency. The distribution is identical for edema except for feet, which are very often affected [1–4].

Textbooks and narrative reviews state that Finkelstein-Seidlmayer vasculitis is often preceded by a respiratory tract infection, a gastroenteritis, a urinary tract infection, a benign febrile disease with unknown source, or a vaccine [2, 4]. To better understand the interplay between infections or vaccines and Finkelstein-Seidlmayer vasculitis, we utilized the data contained in the Acute Hemorrhagic Edema Bibliographic Database AHEBID.

Methods

AHEBID was initiated by some of us [3, 5, 6] in 2019, is being regularly updated and encompasses the entire original literature on Finkelstein-Seidlmayer vasculitis published after the original description in 1913 [7]. The database is attainable on request (email: finkelstein-seidlmayer@usi.ch). For this purpose, the bibliography search engines Excerpta Medica, the National Library of Medicine database and Google scholar are screened every second month for “acute hemorrhagic edema”, “cockade purpura and edema”, “Finkelstein-Seidlmayer” and “infantile Henoch-Schönlein purpura” without any language restriction. To increase the rigor of the literature search, we conduct the search in agreement with 2020 version of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. AHEBID also incorporates secondary references and the literature on Finkelstein-Seidlmayer vasculitis collected by one of us in the early eighties of the last century [8]. As of September 1, 2021, the database (Fig. 1) included 314 (see: supplementary material) original reports (letters, case reports or full-length articles) published after 1969, which addressed 504 (349 boys and 155 girls) individually documented cases: 7 neonates less than 4 weeks of age, 252 infants less than 12 months of age, 181 infants 12 to 23 months of age and 63 children 24 months or more of age (this piece of information was not available in one case). For all patients, the diagnosis of hemorrhagic edema made in the original reports was reviewed using three well established clinical criteria: raised annular or nummular eruptions and inflammatory skin edema (mostly non-pitting, tender and sometimes also warmth) in a well-appearing and playful child with stable vital signs [5]. The clinical diagnosis was supported by a skin biopsy [9] disclosing a non-granulomatous neutrophil infiltration into small-vessel walls with karyorrhexis in 248 (50%) cases.

For the present study, we meticulously extracted published cases of Finkelstein-Seidlmayer vasculitis where the existence of an associated infectious or vaccine precursor (by 14 days or less) was discussed [4, 5]. The temporal relationship between infection and onset of Finkelstein-Seidlmayer vasculitis was employed to classify the condition as intra- (skin vasculitis starting before resolution of the infection) or post-infectious (skin disorder starting after resolution of the infection). The term latency was used to denote the time (in days) elapsed from onset of infectious symptoms to onset of skin eruption. The infectious precursors [10–12] were classified as depicted in Table 1.

Categorical variables are shown as counts and were analyzed using the Fisher’s exact test. Numerical variables are presented as medians and interquartile ranges and were compared using the Mann–Whitney U test. Two-sided P-values of less than 0.05 were regarded as statistically significant.

Results

The possible existence of an infectious or a vaccine precursor was addressed in 447 cases and not addressed in the remaining 57 cases (Fig. 2). Cases with this piece of information were slightly younger than cases without it (11 [8–18] months of age vs 14 [9–21] months of age, P < 0.05). The male-to-female ratio was similar in the two groups (309 boys and 138 girls, respectively, 40 boys and 17 girls). Most cases were preceded by an infection (86%), by a vaccination (4.4%), or both an infection and a vaccination (3.8%). No precursor was reported in the remaining cases (5.8%). Two distinct infections preceded the onset of the skin eruptions in 11 of the 384 cases with infection-associated Finkelstein-Seidlmayer vasculitis.

The 449 precursors noted in 423 infants are given in Fig. 3. Most cases were preceded by an upper respiratory tract infection (65%), followed by a vaccine (8.2%), a gastroenteritis (8.9%), a benign febrile infection (8.0%) or a lower respiratory infection (4.9%).
Ninety-seven microorganisms possibly causing the infectious precursor were detected in 85 infants: 54 bacteria, 41 viruses, and 2 fungi (Table 2).

The temporal relationship between the infectious precursor and the onset of the skin eruption was not detailed in 65 cases (47 boys and 18 girls, 11 [8–18] months of age). This parameter was reported in the remaining 336 cases (230 boys and 106 girls, 11 [8–17] months of age). Fifty-three cases (38 boys and 15 girls, 11 [7–14] months of age) were intra- and 283 (191 boys and 92 girls, 11 [8–17] months of age) post-infectious (Table 3).

The latency time was significantly lower in the 23 intra-infectious cases (P < 0.001) as compared with the 205 post-infectious cases.

In 37 cases (24 males and 13 females, 12 [7–18] months of age), the skin eruptions were preceded by one or more active immunizations (Table 4). The temporal relationship between the vaccination and the onset of this vasculitis was not described in 10 cases (8 boys and 2 girls, 17 [8–20] months of age). The latency time was 7 [3–13] days in the remaining 27 cases (16 boys and 11 girls, 12 [7–18] months of age).
Table 1 Classification of infections utilized for the present analysis

- **Acute upper respiratory tract infection**
  - One or more of the following signs: purulent nasal discharge; cough; red, bulging tympanic membrane with loss of normal landmarks; purulent ear discharge; pharyngo-tonsillar erythema or exudate
  - The term was also employed for patients diagnosed with common cold, pharyngitis, tonsillitis, or otitis media in the original report

- **Acute lower respiratory tract infection (including pneumonia)**
  - Cough associated with one or more of the following signs: labored breathing; chest indrawing; rales; stridor; wheezing; cyanosis; respiratory rate > 50/min
  - The term was also employed for cases diagnosed with croup, bronchitis, bronchiolitis, or pneumonia in the original report

- **Acute lower respiratory tract infection (including pneumonia)**
  - Cough associated with one or more of the following signs: labored breathing; chest indrawing; rales; stridor; wheezing; cyanosis; respiratory rate > 50/min
  - The term was also employed for cases diagnosed with croup, bronchitis, bronchiolitis, or pneumonia in the original report

- **Acute gastroenteritis**
  - Three or more loose stools per day (or a number of bowel movements exceeding the child’s usual number of daily bowel movements by two or more) with or without associated fever and vomiting
  - The term was also employed for cases diagnosed with acute gastroenteritis or acute infectious diarrhea in the original report

- **Urinary tract infection**
  - Increased body temperature, failure to thrive, poor feeding or acute urinary symptoms associated with urinalysis disclosing a pathological pyuria and a significant positive urine culture (excluding lactobacilli, corynebacteria, and coagulase-negative staphylococci)
  - The term was also employed for cases diagnosed with urinary tract infection or pyelonephritis in the original report

- **Benign febrile infection without a source**
  - Fever in a previously healthy, otherwise well-appearing child when a complete history and physical examination do not identify a specific source of infection. Occult infections such as urinary tract infection, bacteremia or pneumonia have also been reasonably excluded
  - The term was also employed for cases diagnosed with benign febrile infection, fever without localizing signs or fever without a focus in the original report

- **Further infections**
  - The diagnosis made in the original report was retained

Fig. 2 Finkelstein-Seidlmayervasculitis. Precursors. The term AHEBID denotes the Acute Hemorrhagic Edema Bibliographic Database

Finkelstein-Seidlmayervasculitis Possible Precursors

![Diagram showing classification of infections](image)

- **AHEBID Cases N=504**
  - **No information N=57**
  - **Included Cases N=447**
    - **No Precursor N=26**
    - **Infection N=384***
    - **Infection and vaccination N=17**
    - **Vaccination N=20**

* Two infections in 11 cases
Discussion

This systematic literature review documents that most cases of Finkelstein-Seidlmayer vasculitis are preceded by an infection. In a minority of cases, this skin vasculitis develops before resolution of the infection, i.e., intra-infectiously. In the vast majority of cases, however, this vasculitis develops after resolution of the infection, i.e., post-infectiously. More rarely, this vasculitis is preceded by a vaccination or both an infection and a vaccination, indicating that infections by far more frequently trigger immune-mediated diseases than vaccinations.

The reason for the unique distribution of skin lesions with predilection for face and ears remains unclear. The following possible explanations may be offered. In immunoglobulin A vasculitis, the location of skin lesions is notoriously gravity-dependent. Since infants with Finkelstein-Seidlmayer vasculitis spend most of their time lying down, gravity cannot play a role. The main factor that may modulate the distribution of lesions is the blood supply: the proportionally large head and face with a corresponding increase in blood supply in infants predisposes them more to facial lesions. A predilection for the face is observed also in infants with strawberry hemangioma, where the subcutaneous arteries that nourish the hemangioma are mostly found in the head [4]. Finally, it is tempting to assume a role also for skin-resident cells.

Infectious causes have long been suspected for many vasculitis syndromes [13, 14]. In most cases, the vascular injury has been ascribed to immune-mediated mechanisms rather than direct microbial invasion [13, 14]. There is a recognized association between some vasculitides and infections: Mycobacterium tuberculosis is likely involved in Takayasu arteritis [15] and a Burkholderia in Horton giant cell arteritis [16]; Hepatitis B and C viruses have been associated to polyarteritis nodosa [17]; Staphylococcus aureus has been the focus of many studies on granulomatosis with polyangiitis [18]; finally, Hepatitis C virus is a cause of cryoglobulinemia vasculitis [19]. Immunoglobulin A–associated small-vessel leukocytoclastic vasculitis has been associated with bacteria such as group A Streptococci, atypical bacterial pathogens (including Mycoplasma), Helicobacter pylori, Staphylococcus aureus, Salmonella enteritidis or Campylobacter, and with viruses such as Parvovirus B19, Varicella-zoster virus, Epstein-Barr virus and especially common respiratory viruses [20]. Very recently, immunoglobulin A vasculitis has also been associated with severe acute respiratory syndrome coronavirus 2 [21].

The precursors noted in Finkelstein-Seidlmayer vasculitis are concurrently similar and different from those observed in immunoglobulin A vasculitis. Both Finkelstein-Seidlmayer vasculitis and immunoglobulin A vasculitis are often preceded either by a vaccination or, more frequently, an infection. However, Streptococcus pyogenes and atypical bacterial pathogens including Mycoplasma very often precede immunoglobulin A vasculitis but rather rarely precede Finkelstein-Seidlmayer vasculitis [20, 22, 23]. This difference is likely related to the fact that Streptococcus pyogenes [24] and atypical bacterial pathogens [25] rarely affect subjects 4–5 years or less of age. Textbooks and reviews sometimes emphasize an unproven association between Mycoplasma and Finkelstein-Seidlmayer vasculitis. This misunderstanding likely reflects the fact that the clinical hallmarks of this vasculitis resemble erythema multiforme, a condition often caused by Mycoplasma [1–4]. Our data also demonstrate that, like with immunoglobulin A vasculitis, respiratory tract viruses including coronavirus disease 2019 [26] may be associated with Finkelstein-Seidlmayer vasculitis. Vaccination against severe acute respiratory syndrome coronavirus 2 has also been occasionally associated...
Table 2 Microorganisms (N = 97) associated with the infectious precursor in 85 patients (65 males and 20 females; 10 [7–14] months of age) with Finkelstein-Seidlmayer vasculitis

| Bacteria                        | N  |
|---------------------------------|----|
| Streptococcus species           | 54a|
| Streptococcus pyogenes          | 20 |
| Streptococcus pneumonia         | 11 |
| Streptococcus not otherwise specified | 5  |
| Streptococcus viridans          | 3  |
| Escherichia coli                | 12 |
| Mycoplasma pneumoniae           | 6  |
| Staphylococcus species          | 4  |
| Staphylococcus aureus           | 2  |
| Staphylococcus not otherwise specified | 2  |
| Campylobacter species           | 3  |
| Campylobacter jejuni            | 2  |
| Campylobacter mucosalis         | 1  |
| Proteus mirabilis               | 3  |
| Mycobacterium tuberculosis      | 2  |
| Gram-positive bacterium, not otherwise specified | 1  |
| Gram-negative bacterium, not otherwise specified | 1  |
| Haemophilus influenzae          | 1  |
| Salmonella not otherwise specified | 1  |
| Viruses                         | 41 |
| Herpesviridae                   |    |
| Human Herpes Virus 3 (Varicella Zoster Virus) | 4  |
| Human Herpes Virus 1 (Herpes simplex 1) | 2  |
| Human Herpes Virus 4 (Epstein-Barr Virus) | 2  |
| Human Herpes Virus 5 (Cytomegalovirus) | 1  |
| Adenovirus                      | 5  |
| Rhinovirus                      | 4  |
| Coronaviruses                    | 4  |
| Severe acute respiratory syndrome coronavirus | 3  |
| Coronavirus NL63                | 1  |
| Picornaviruses                   |    |
| Coxsackievirus not otherwise specified | 1  |
| Coxsackievirus B4               | 1  |
| Coxsackievirus B5               | 1  |
| Enterovirus not otherwise specified | 3  |
| Parvovirus B19                  | 3  |
| Rotavirus                       | 3  |
| Bocavirus                       | 1  |
| Echovirus                       | 1  |
| Hepatitis A virus               | 1  |
| Human metapneumovirus           | 1  |
| Parainfluenza virus             | 1  |
| Paramyxovirus                   | 1  |
| Fungi                            |    |
| Candida albicans                | 2  |

a in 47 patients
b in 26 patients
with immunoglobulin A vasculitis [27]. On the contrary, no cases of Finkelstein-Seidlmayer vasculitis have been so far associated with this vaccination, likely because it is currently not recommended in young children. Finally, it is worth of mention that a temporal association between an infection (or a vaccination) and Finkelstein-Seidlmayer vasculitis does not inexorably and in every case imply causality.

Immunoglobulin A vasculitis is obviously an immunoglobulin A dominant vasculitis [2, 4]. Since immunoglobulin A is an early response to a pathogen, the clinical features of this vasculitis mostly occur before resolution of the infectious precursor, i.e., intra-infectiously [2, 4]. Finkelstein-Seidlmayer vasculitis is a non-immunoglobulin A dominant immune-mediated vasculitis. Consequently, the features of this vasculitis mostly occur after resolution of the infection, i.e., post-infectiously.

Table 3 Characteristics of patients with post- or intra-infectious Finkelstein-Seidlmayer vasculitis. Data are given as median and interquartile range or as frequency

|                      | Post-infectious | Intra-infectious | P-value |
|----------------------|-----------------|------------------|---------|
| N                    | 283             | 53               |         |
| Males: females, N    | 191: 92         | 38: 15           | 0.528   |
| Age, months          | 11 [8–17]       | 11 [7–14]       | 0.230   |
| Latency, days        | 7a [4–14]       | 2b [1–3]        | < 0.001 |

Precursor

|                      | Post-infectious | Intra-infectious | P-value |
|----------------------|-----------------|------------------|---------|
| Upper respiratory infection, N (%) | 222 (78%) | 31 (58%) | < 0.005 |
| Acute gastroenteritis, N (%)       | 30 (11%)   | 4 (7.5%)     | 0.625   |
| Lower respiratory infection, N (%) | 14 (4.9%) | 5 (9.4%)    | 0.204   |
| Urinary tract infection, N (%)     | 11 (3.9%)  | 2 (3.8%)     | 0.999   |
| Benign febrile infection, N (%)    | 10 (3.5%)  | 3 (5.7%)     | 0.445   |
| Further infections, N (%)          | 5 (1.8%)   | 9 (17%)      | < 0.001 |

*aInformation available for 205 cases
*bInformation available for 23 cases

The results of this systematic review must be viewed with an understanding of the inherent limitations of the analysis process, which integrated information from reports detailing on average one to two cases of Finkelstein-Seidlmayer vasculitis reported over a period of 50 years. For example, the diagnostic strategy was heterogeneous: it was often supported by a skin biopsy study in cases managed by dermatologists but was made clinically in those managed by pediatricians. The obvious strength of this analysis is that it includes the whole literature on this vasculitis over the period 1970–2021.

Conclusions

In Finkelstein-Seidlmayer vasculitis (like in immunoglobulin A vasculitis), it is typical that different infectious agents may trigger the same pathological damage. On the other hand, a specific microbe may produce more than one vasculitis syndrome. The mechanisms underlying the occurrence of an infection-associated immune-mediated vasculitis are still speculative. It is currently postulated that bystander activation, microbial persistence, or molecular mimicry [28] and genetic factors [29] concurrently play a crucial role.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s12016-022-08940-2.

Author Contribution G.B., P.O.R., M.G.B., S.A.G.L., and G.P.M. developed the Acute Haemorrhagic Edema Bibliographic Database; G.B., M.G.B., and G.P.M. conceptualized the study design; G.B. and P.O.R. extracted the data; G.B., C.B., D.C. and S.A.G.L. analyzed the data; L.K., M.M.B., and B.T.B.P. contributed to data interpretation; G.B., M.G.B., G.P.M., and B.T.B.P. wrote the manuscript; L.K., M.M.B. and B.T.B.P. revised the manuscript; C.B. and D.C. reviewed the manuscript for important intellectual content; All authors read and commented on the final version of the manuscript.
Funding Open access funding provided by Università della Svizzera italiana. Dr. Lava is the current recipient of research grants from Fonds de perfectionnement, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Fondation SICPA, Prilly, Switzerland; Fondazione Dr. Ettore Balli, Bellinzona, Switzerland; and Fondazione per il bambino malato della Svizzera italiana, Bellinzona, Switzerland. Dr. Bett is supported by an internal funding from Ente Ospedaliero Cantonale for junior researchers.

Declarations

Ethics Approval and Consent to Participate This was a systematic review study that in our institutions does not require specific ethics approval.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Fiore E, Rizzi M, Ragazzi M, Vanoni F, Bernasconi M, Bianchetti MG, Simonetti GD (2008) Acute hemorrhagic edema of young children (cockade purpura and edema): a case series and systematic review. J Am Acad Dermatol 59(4):684–695. https://doi.org/10.1016/j.jaad.2008.06.005
2. Ting TV (2014) Diagnosis and management of cutaneous vasculitis in children. Pediatr Clin North Am 61(2):321–346. https://doi.org/10.1016/j.pcl.2013.11.007
3. Rinoldi PO, Bronz G, Ferrari A, Mangas C, Bianchetti MG, Chelleri C, Lava SAG, Milani GP (2021) Acute hemorrhagic edema: uncommon features. J Am Acad Dermatol 85(6):1620–1621. https://doi.org/10.1001/jaad.2020.12.033
4. Lava SAG, Milani GP, Fossali EF, Simonetti GD, Agostoni C, Bianchetti MG (2017) Cutaneous manifestations of small-vessel leukocytoclastic vasculitides in childhood. Clin Rev Allergy Immunol 53(3):439–451. https://doi.org/10.1007/s12016-017-8626-3
5. Rinoldi PO, Milani GP, Bianchetti MG, Ferrari A, Ramelli GP, Lava SAG (2019) Acute hemorrhagic edema of young children: open questions and perspectives. Int J Dermatol Skin Care 1:63–67. https://doi.org/10.3681/ijdsc.2019.110003
6. Bronz G, Consolascio D, Bianchetti MG, Rinoldi PO, Betti C, Lava SAG, Milani GP (2022) Köbner and Pastea signs in acute hemorrhagic edema of young children: systematic literature review. Children 9(2):265. https://doi.org/10.3390/children9020265
7. Snow IM (1913) Purpura, urticaria and angioneurotic edema of the hands and feet in a nursing baby. JAMA 61(1):18–19. https://doi.org/10.1001/jama.1913.04350100120008
8. Boell SK, Ceecez-Kecmanovic D (2015) On being ‘systematic’ in literature reviews in IS. J Inf Technol 30:161–173
9. Frumholtz L, Laurent-Roussel S, Lipsker D, Terrier B (2021) Cutaneous vasculitis: review on diagnosis and clinicopathologic correlations. Clin Rev Allergy Immunol 61(2):181–193. https://doi.org/10.1007/s12016-020-08788-4
10. Koch A, Sørensen P, Homse P, Mollbak K, Pedersen FK, Mortensen T, Elberling H, Eriksen AM, Olsen OR, Melbye M (2002) Population-based study of acute respiratory infections in children. Greenland Emerg Infect Dis 8(6):586–593. https://doi.org/10.3201/eid0806.010321
11. Whyte LA, Al-Arajia RA, McLoughlin LM (2015) Guidelines for the management of acute gastroenteritis in children in Europe. Arch Dis Child Educ Pract Ed 100(6):308–312. https://doi.org/10.1136/archdischild-2014-307253
12. Buettcher M, Traue J, Niederer-Leher A, Heininger U, Agyeman P, Asner S, Berger C, Bielicki J, Kahler C, Kottanattu L, Meyer Sauteur PM, Paioni P, Posfay-Barbe K, Kelly C, Ritz N, Zimmermann P, Zucol F, Gobet R, Shavit S, Rudin C, Laube G, von Vigitel R, Neuhaus TJ (2021) Swiss consensus recommendations on urinary tract infections in children. Eur J Pediatr 180(3):663–674. https://doi.org/10.1007/s00431-020-03714-4
13. Lie JT (1996) Vasculitis associated with infectious agents. Curr Opin Rheumatol 8(1):26–29. https://doi.org/10.1097/0000281-199601000-00004
14. van Timmeren MM, Heeringa P, Kallenberg CG (2014) Infectious triggers for vasculitis. Curr Opin Rheumatol 26(4):413–23. https://doi.org/10.1097/BOR.0000000000000068
15. Seyahi E (2017) Takayasu arteritis: an update. Curr Opin Rheumatol 29(1):51–56. https://doi.org/10.1097/BOR.0000000000000343
16. Younger DS (2019) Giant cell arteritis. Neurol Clin 37(2):335–344. https://doi.org/10.1016/j.ncl.2019.01.008
17. Forrest L, Banukh S (2015) Polyrheutis nodosa. Rheum Dis Clin North Am 41(1):33–46. https://doi.org/10.1016/j.rdc.2014.09.005
18. Banerjee P, Jain A, Kumar U, Senapati S (2021) Epidemiology and genetics of granulomatosis with polyangiitis. Rheumatol Int 41(12):2069–2089. https://doi.org/10.1007/s00296-021-05011-1
19. Desbois AC, Cacoub P, Saadoun D (2019) Cryoglobulinemia: an update in 2019. Joint Bone Spine 86(6):707–713. https://doi.org/10.1016/j.jbspin.2019.01.016
20. Rigante D, Castellazzi L, Bosco A, Esposito S (2013) Is there a crossroad between infections, genetics, and Henoch-Schönlein purpura? Autoimmun Rev 12(10):1016–1021. https://doi.org/10.1016/j.autrev.2013.04.003
21. Jacobi M, Lancrei HM, Brosh-Nissimov T, Yeshayahu Y (2021) Purpura: a novel report of COVID-19-related Henoch-Schönlein purpura in a child. Pediatr Infect Dis J 40(2):e93–e94. https://doi.org/10.1097/INF.0000000000003001
22. Betti C, Camozzi P, Gennaro V, Bianchetti MG, Scoglio M, Simonetti GD, Milani GP, Lava SAG, Ferrari A (2021) Atypical bacterial pathogens and small-vessel leukocytoclastic vasculitis of the skin in children: systematic literature review. Pathogens 10(1):31. https://doi.org/10.3390/pathogens10010031
23. Wang JJ, Xu Y, Liu FF, Wu Y, Samadli S, Wu YF, Luo HH, Zhang DD, Hu P (2020) Association of the infectious triggers with childhood Henoch-Schönlein purpura in Anhui province. Chin J Infect Public Health 13(1):110–117. https://doi.org/10.1016/j.jiph.2019.07.004
24. Dietrich ML, Steele RW (2018) Group A Streptococcus. Pediatr Rev 39(8):379–391. https://doi.org/10.1542/pir.2017-0207
25. Atkinson TP, Waites KB (2014) Mycoplasma pneumoniae infections in childhood. Pediatr Infect Dis J 33(1):92–94. https://doi.org/10.1097INF.0000000000000171
26. El Hasbani G, Taher AT, Jawad ASM, Uthman I (2021) Henoch-Schönlein purpura: another COVID-19 complication. Pediatr Dermatol 38(5):1359–1360. https://doi.org/10.1111/pde.14699
27. Hines AM, Murphy N, Mullin C, Barillas J, Barrientos JC (2021) Henoch-Schönlein purpura presenting post COVID-19 vaccination. Vaccine 39(33):4571–4572. https://doi.org/10.1016/j.vaccine.2021.06.079
28. Fujinami RS, von Herrath MG, Christen U, Whitton JL (2006) Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 19(1):80–94. https://doi.org/10.1128/CMR.19.1.80-94.2006

29. Salama AD (2018) Genetics and pathogenesis of small-vessel vasculitis. Best Pract Res Clin Rheumatol 32(1):21–30. https://doi.org/10.1016/j.berh.2018.10.002

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.